Nano PharmaSolutions, Inc. is structured around development of a drug delivery platform for poorly soluble drugs in preclinical and post-approval stages. The firm's proprietary nanoformulation does not use solvent, polymers, or other extrinsic chemicals and is easily scalable. Offering a phase-transition technology platform that can quickly and reliably enhance the solubility of BCS 2 and BCS 4 APIs without the use of excipients (e.g. large volumes of volatile solvents) used in such processes as spray dry dispersion, hot melt extrusion and emulsification. the firm's patented technology platform uniformly deposits vaproized API onto the surface of a carrier molecule which is further processable into the full spectrum of existing dosage forms.
